Edwards MITRIS RESILIA Valve Receives CE Mark for Mitral Replacement Surgeries
Edwards Lifesciences today announced it received CE Mark for the MITRIS RESILIA valve, a tissue valve replacement specifically designed for the heart's mitral position. The MITRIS RESILIA valve is made with innovative bovine pericardial tissue technology that reduces calcium build up on the valve. This technology preserves and protects the tissue, allowing the valve to potentially last longer than conventional bioprosthetic valves.*
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231025088486/en/
The MITRIS RESILIA valve is made with innovative tissue technology RESILIA allowing the valve to potentially last longer than conventional bioprosthetic valves.* (Photo: Business Wire)
The MITRIS RESILIA valve has a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve. The low-profile valve is based on the Edwards PERIMOUNT valve design with a nitinol wireform, which allows it to fold inward during implantation. The MITRIS RESILIA valve is visible under fluoroscopy, which facilitates potential future transcatheter interventions for patients.
Recent data on the RESILIA tissue from the COMMENCE aortic trial reported encouraging results with low rates of structural valve deterioration (99.3% freedom from structural valve deterioration), clinically stable gradients and freedom from reoperation (97.2%) through seven years. Additionally, the COMMENCE mitral trial demonstrated clinically stable hemodynamics and freedom from structural valve deterioration (98,7%) at 5 years.
The RESILIA anti-calcification technology also allows devices to be stored under dry packaging conditions, facilitating ease of use.
“Mitral valve disease is prevalent and patients experience the disease in various ways. For patients who need mitral valve replacement, the advanced MITRIS RESILIA valve, designed to mimic the native valve, is based on a trusted pericardial PERIMOUNT” says Dr. Daniel Pereda Arnau, Head of Section, Cardiac Surgery Department, H. Clínic de Barcelona. “As valve durability is becoming increasingly important, the integrity-preservation technology incorporated in the RESILIA tissue that will potentially allow the valve to last longer, is critical.”
Edwards is dedicated to partnering with clinicians to develop patient-centric innovations for complex surgical structural heart procedures that improve long-term care and outcomes for patients.
“Edwards Lifesciences is committed to addressing the needs of patients with structural heart disease,” says John Barry, Edwards' Senior Vice President Surgical Europe. “Our RESILIA tissue technology is designed for enhanced durability, supporting improved quality of life for patients and relieving the burden on healthcare systems.”
The MITRIS RESILIA valve received FDA approval in 2022 in the United States. The introduction of the MITRIS RESILIA valve into the portfolio demonstrates Edwards’ continuous investment in innovation for the benefits and the quality of life of patients.
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on LinkedIn and Twitter.
Edwards, Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Carpentier-Edwards PERIMOUNT, MITRIS, MITRIS RESILIA, PERIMOUNT, and RESILIA are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. This statement is made on behalf of Edwards Lifesciences Corporation and its subsidiaries.
*No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231025088486/en/
Contact information
Media Contact:
Julie Tracol, +41 (0)75 431 74 95
Julie_tracol@edwards.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces European Commission Approval of Minjuvi ® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma17.12.2025 17:20:00 CET | Press Release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy. "The EC approval of Minjuvi addresses a critical need, bringing a new, first-of-its-kind, chemotherapy-free option to patients in Europe with relapsed or refractory FL,” said Bill Meury, President and Chief Executive Officer, Incyte. “Historically, FL patients have had limited treatment options in the second-line setting, and we are proud to drive this important advancement for the lymphoma community as we seek to deliver innovative medicines for patients with cancer.” The EC decision follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in November 2025. This marks the second indication for Minjuvi, which was previo
Rigaku Launches ONYX 3200, a Metrology Instrument for Semiconductor Manufacturing17.12.2025 16:00:00 CET | Press Release
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) announced the launch of the ONYX 3200, a new semiconductor metrology system to measure film thickness, composition and bump* structures for wafer-level processes. The system is engineered to help manufacturers stabilize quality and increase yield in the metal-wiring formation (back-end-of-line (BEOL)) and packaging processes of semiconductor chips. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216597402/en/ ONYX 3200 Due to accelerating demands for AI, high-performance computing, data centers, mobile devices, and other devices, chip wiring and interconnect structures have grown increasingly delicate and complex. As a result, the ability to accurately and non-destructively measure metal layers thinner than a human hair and bump
Taylor Wessing Diversifies Its International Strategy17.12.2025 15:05:00 CET | Press Release
International law firm Taylor Wessing is set to diversify its strategy within its international alliance, in order to push international growth and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217415857/en/ Dr. Oliver Bertram, Global Co-Chair at Taylor Wessing The English part of the partnership is seeking a merger with US law firm Winston & Strawn and would – depending on a corresponding partner decision, which is still pending – leave the Taylor Wessing alliance at the end of April 2026. Both parties wish to continue their successful joint international client work unchanged. Therefore, collaboration between Taylor Wessing and future Anglo-American firm Winston Taylor will continue seamlessly based on a cooperation agreement, ensuring that clients will not experience any change in their collaboration with Taylor Wessing. With the firm’s new open strategy, Taylor Wessing equally meets the strategic requirem
ISACA to Lead Global Credentialing for CMMC Cybersecurity Framework as International Cyber Readiness Standards Rise17.12.2025 15:00:00 CET | Press Release
As cyber threats escalate and governments raise expectations around operational resilience, ISACA has been appointed to lead the global credentialing programme for the U.S. DoW’s Cybersecurity Maturity Model Certification (CMMC) program. The appointment positions ISACA – the international association for cybersecurity, audit and digital trust – as the exclusive CMMC Assessor and Instructor Certification Organization (CAICO), responsible for training, examining and certifying professionals, assessors, and instructors across the CMMC ecosystem. Originally developed by the U.S. DoW to protect sensitive unclassified information within its global supply chain, CMMC is increasingly relevant to European defence, aerospace, engineering and high-technology companies participating in transatlantic programmes. As the framework is phased into U.S. procurement from 2025 to 2028, many European organisations that handle Controlled Unclassified Information (CUI) or Federal Contract Information (FCI),
ASN Bank Signs a Contract With HCLTech to Accelerate Digital Transformation and Enhance Customer Experience17.12.2025 14:43:00 CET | Press Release
HCLTech, a leading global technology company, today announced that it has been selected as a strategic partner by ASN Bank (formerly de Volksbank), the fourth-largest retail bank in the Netherlands. As part of its new strategy ‘Simplify and Grow’, ASN Bank aims to modernise and standardise its IT architecture, which will involve consolidating IT services, simplifying the vendor landscape and building a future-ready organisation. Under the multi-year agreement, HCLTech will support ASN Bank’s enterprise applications, and streamline services through a distributed delivery model to enhance efficiency and customer experience. Michel Ruijterman, Chief Information Officer, ASN Bank: “By signing this agreement , HCLTech’s proven track record in delivering scalable, innovative solutions tailored to the financial services sector means we can now confidently press on with streamlining our business by reducing the number of existing products and aligning the underlying processes and systems under
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom